C
4.46
-0.02 (-0.45%)
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 混合的 | 看涨 |
| Biotechnology (全球的) | 混合的 | 看涨 | |
| 股票 | CARGO Therapeutics, Inc. | 混合的 | 混合的 |
AIStockmoo 评分
| 分析师共识 | 0.0 |
| 内部交易活动 | NA |
| 价格波动 | -0.6 |
| 技术平均移动指标 | -2.5 |
| 技术振荡指标 | 0.0 |
| 相对估值 | NA |
| 财务健康 | 0.0 |
| 宏观环境 | -1.3 |
| AI Insight | NA |
| AI Technical | NA |
| 平均 | -0.80 |
|
Cargo Therapeutics Inc is a clinical-stage biotechnology company positioned to advance next generation, potentially curative cell therapies for cancer patients. It programs, platform technologies, and manufacturing plan are designed to directly address the key limitations of approved cell therapies, including limited durability of effect, suboptimal safety and unreliable supply. The company's program, CRG-022, is a novel CAR T-cell product candidate designed to address resistance mechanisms by targeting CD22, an alternate tumor antigen that is expressed in a vast majority of B-cell malignancies. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 内部持股比例 | 0.65% |
| 机构持股比例 | 101.53% |
该时间范围内无数据。
该时间范围内无数据。
投资组合